HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025

Rhea-AI Summary

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), announces an upcoming investor workshop for Qualified Institutional Investors at Mar-A-Lago Club during the week of January 6, 2025. The event aims to support planned acquisitions for a national network of interventional psychiatry practices focused on treating suicidal depression and PTSD.

The company has secured non-binding Letters of Intent and banking intent for initial clinic acquisitions, targeting facilities that generate over $100 million revenue run-rate in 2025. Future acquisitions will focus on clinics with established patient populations offering multimodal care, including ketamine treatment and Transcranial Magnetic Stimulation (TMS).

The workshop requires a minimum commitment of $5 million in secured acquisition funding from qualified investors. The presentation will comply with JOBS act 'testing the waters' provisions, and federal security clearance will be required for attendance.

Positive

• Company has secured non-binding Letters of Intent for clinic acquisitions
• Target acquisitions expected to generate over $100 million revenue run-rate in 2025
• Strategic expansion into established clinics with existing patient bases and multiple treatment modalities

Negative

• Letters of Intent are non-binding, indicating uncertainty in deal completion
• Significant capital requirements ($5M minimum) needed for acquisition strategy

Insights

Financial Analyst

The planned acquisition strategy by HOPE Therapeutics represents a significant business expansion into the mental health treatment sector. The target of acquiring clinics with $100 million revenue run-rate in 2025 indicates an aggressive growth strategy in the interventional psychiatry space. However, several critical factors warrant careful consideration:

The focus on ketamine treatment and TMS clinics aligns with the growing mental health treatment market, particularly for treatment-resistant depression and PTSD. The acquisition strategy could provide rapid revenue scaling, but integration challenges and operational complexities in managing a nationwide network need careful evaluation. The $5 million minimum commitment requirement from qualified institutional investors suggests a structured approach to funding, though the total capital needs for the planned acquisitions remain unclear.

For a company with a market cap of just $37 million, this ambitious expansion plan represents a significant transformation that could substantially alter the company's financial profile. The success will largely depend on execution capability, integration efficiency and ability to maintain quality across acquired clinics.

Healthcare Industry Specialist

The strategic focus on interventional psychiatry practices, particularly those offering ketamine and TMS treatments, positions HOPE Therapeutics at the intersection of two growing trends: the mental health crisis and innovative treatment modalities. The targeting of established clinics with mature patient populations reduces initial patient acquisition costs and provides immediate revenue streams.

However, the fragmented nature of psychiatric practices and varying state regulations could present operational challenges in creating a standardized national network. The emphasis on multimodal care facilities indicates a comprehensive treatment approach, which could provide competitive advantages but also increases operational complexity.

The appointment of Dr. David Feifel as Chief Medical Innovation Officer, known for his work in neuropsychiatry, suggests a focus on maintaining clinical excellence while scaling. This workshop appears designed to secure funding for the next phase of an already-in-motion acquisition strategy, rather than testing initial market interest.

MIAMI, Jan. 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) subsidiary, is inviting Qualified Institutional Investors to an investor workshop to support planned acquisitions for a national network of interventional psychiatry practices focused on treatment suicidal depression and PTSD. The Company has previously announced non-binding Letters of Intent and banking intent for initial clinic acquisitions and has disclosed its intent to acquire and integrate clinics generating a more than $100 million revenue run-rate in 2025. Future HOPE acquisitions under consideration have mature patient populations and already provide multimodal care including ketamine treatment and Transcranial Magnetic Stimulation (TMS).

Jonathan Javitt, MD, MPH, Chairman, Co-CEO of HOPE Therapeutics and Chairman and Chief Scientist of NRx Pharmaceuticals, and David Feifel, MD, PhD, the designated Chief Medical Innovation Officer of HOPE Therapeutics, will provide a corporate update and entertain questions related to future HOPE clinic acquisitions.

The investor workshop will be conducted during the week of January 6, 2025 at a time to be disclosed to cleared participants. Qualified Institutional Investors, according to the definition of the US Securities and Exchange Commission, who may be prepared to commit a minimum of $5 million in secured acquisition funding for the next tier of acquisitions, are invited to contact Matthew Duffy, Co-CEO (information below) for more details.  Information to be presented will be within the "testing the waters" provisions of the JOBS act. Federal security clearance information will be required for prospective attendees.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional  psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding closing the acquisition of Kadima and obtaining financing necessary to consummate the acquisition. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-an-nrx-pharmaceuticals-inc-nasdaqnrxp-subsidiary-will-host-an-investor-workshop-for-qualified-institutional-investors-at-the-mar-a-lago-club-during-the-week-of-january-6-2025-302341699.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

What is HOPE Therapeutics' revenue target for clinic acquisitions in 2025 (NRXP)?

HOPE Therapeutics aims to acquire and integrate clinics generating more than $100 million revenue run-rate in 2025.

What is the minimum investment requirement for NRXP's HOPE Therapeutics investor workshop?

Qualified Institutional Investors must be prepared to commit a minimum of $5 million in secured acquisition funding.

What types of treatment services will HOPE Therapeutics' acquired clinics offer (NRXP)?

The clinics will provide multimodal care including ketamine treatment and Transcranial Magnetic Stimulation (TMS) for treating suicidal depression and PTSD.

When and where will HOPE Therapeutics' investor workshop take place (NRXP)?

The workshop will be held at the Mar-A-Lago Club during the week of January 6, 2025, with specific timing to be disclosed to cleared participants.